Table 1 Study populations.

From: Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma

  N Per cent male Age at diagnosis (years±s.d.) Genotyping method
Discovery samples
 Sweden and Norway
Cases 1,714 57.1% 67.5±11.4 Illumina OmniExpress-Exome1
Controls 10,391 51.5% Illumina OmniExpress1
 Iceland (MM)
Cases 480 47.9% 71.2±10.0 Illumina microarrays (n=174); familially imputed (n=306)2
Controls 212,164 48.9% Illumina microarrays (n=82,742); familially imputed (n=129,422)2
 Iceland (MM+MGUS)
Cases 731 49.5% 71.0±12.4 Illumina microarrays (n=332); familially imputed (n=399)2
Controls 283,999 48.8% Illumina microarrays (n=90,568); familially imputed (n=193,431)2
Replication samples
 Sweden
Cases 223 Selected SNPs
Controls 1,285 Selected SNPs
 Denmark
Cases 363 Selected SNPs
Controls 826 Selected SNPs
  1. MGUS, monoclonal gammopathy of unknown significance; MM, multiple myeloma; SNP, single-nucleotide polymorphism.
  2. 1Imputed using whole-genome sequence data from 1,000 Genomes.
  3. 2Imputed using whole-genome sequence data from 2,636 Icelanders.